Suven Life Sciences Ltd
NSE:SUVEN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
77.25
164.66
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Suven Life Sciences Ltd
Suven Life Sciences Ltd
Long-Term Debt
Suven Life Sciences Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Suven Life Sciences Ltd
NSE:SUVEN
|
Long-Term Debt
₹0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Long-Term Debt
₹20m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Long-Term Debt
₹5.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Long-Term Debt
₹5.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Tarsons Products Ltd
NSE:TARSONS
|
Long-Term Debt
₹1.1B
|
CAGR 3-Years
223%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Long-Term Debt
₹2.1B
|
CAGR 3-Years
221%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Suven Life Sciences Ltd
Glance View
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
See Also
What is Suven Life Sciences Ltd's Long-Term Debt?
Long-Term Debt
0
INR
Based on the financial report for Sep 30, 2024, Suven Life Sciences Ltd's Long-Term Debt amounts to 0 INR.
You don't have any saved screeners yet
